Treatment included BCR-ABL tyrosine kinase inhibitors (TKI, n = 66), JAK2-inhibitors (ruxolitinib and fedratinib, n = 32), hydroxyurea (n = 21), steroids (n = 17), rituximab-based regimens (n = 13), interferon-alpha (n = 9), lenalidomide (n = 9), BTK inhibitors (ibrutinib and acalabrutinib, n = 8), immunoglobulin substitution (n = 7), hypomethylating agents and venetoclax (n = 7), any other chemotherapy (n = 7), and other tumor-specific therapies (n = 21). This evidence concerns the gene JAK2 and neoplasm.